Welcome to Diurnal

Founded in 2004, Diurnal is a UK-based, globally-focused specialty pharma company developing products for the life-long treatment of chronic endocrine conditions.

We are committed to addressing major unmet clinical and patient needs in hormone replacement, initially by developing and marketing products for the rare orphan diseases Congenital Adrenal Hyperplasia (CAH) and Adrenal Insufficiency (AI).

Through our extensive knowledge, experience and persistence we have created a specialized, valuable pipeline of product opportunities for the improved treatment of hypogonadism, hypothyroidism and other endocrine disorders, with the primary goal of improving patient outcomes and lives.

Diurnal’s expertise and innovative research activities focus on circadian-based endocrinology (mimicking the body’s natural hormone levels), which has yielded novel product candidates being trialled in patients prior to the submission of a marketing authorisation application.

The company’s knowledge of physiology together with our unique approach of developing circadian-based products utilizing approved drug substances, enables it to judiciously focus on optimising therapeutic performance, principally by altering the drug delivery modality and treatment regimes. This approach also enables Diurnal to significantly de-risk its product development programmes, avoiding the need for much of the substantial and costly pre-clinical development activities and thereby enabling new therapies to be available for patients more quickly.

Diurnal’s product exclusivity is based around specific orphan drug designations, a patented portfolio spanning several product families and in-depth know-how of matching drug delivery solutions to clinical needs.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.